Table 1.
Self-reported past-month prevalence of marijuana use among women aged 12–44 in the U.S., by pregnancy trimester and sociodemographic characteristics, weighted percentage (95% confidence interval), n=410,0001
| Characteristics | Pregnant women aged 12–44 weighted % (95% CI) n=14,400 | Non-pregnant women aged 12–44 weighted % (95% CI) n=395,600 |
|---|---|---|
| Overall Annual Average | 3.82 (3.41–4.23) | 7.54 (7.42–7.66) |
| Trimester | ||
| 1st trimester | 6.44 (5.50–7.53) | |
| 2nd trimester | 3.34 (2.76–4.05) | |
| 3rd trimester | 1.82 (1.41–2.34) | |
| Age | ||
| 12–17 | 14.02 (11.51–16.99) | 6.45 (6.29–6.62) |
| 18–25 | 6.21 (5.57–6.92) | 14.11 (13.85–14.37) |
| ≥26 | 1.77 (1.32–2.38) | 5.17 (5.00–5.35) |
| Race/Ethnicity | ||
| Non-Hispanic white | 3.82 (3.31–4.40) | 8.44 (8.27–8.62) |
| Non-Hispanic black | 6.45 (5.13–8.07) | 8.00 (7.66–8.35) |
| Non-Hispanic other | 1.39 (1.00–1.94) | 5.12 (4.79–5.46) |
| Hispanic | 2.92 (2.17–3.92) | 5.22 (4.98–5.47) |
| Annual Family Income | ||
| <$20,000 | 6.57 (5.60–7.70) | 10.80 (10.50–11.11) |
| $20,000-$49,999 | 3.90 (3.28–4.62) | 7.76 (7.55–7.98) |
| $50,000-$74,999 | 2.80 (1.95–4.00) | 6.19 (5.91–6.48) |
| ≥$75,000 | 1.86 (1.31–2.63) | 5.64 (5.44–5.85) |
| Health Insurance Status | ||
| Private insurance only | 1.82 (1.42–2.34) | 6.49 (6.34–6.64) |
| Uninsured | 7.87 (5.85–10.52) | 9.46 (9.13–9.81) |
| Medicaid | 5.55 (4.89–6.30) | 9.35 (9.04–9.66) |
| Other insurance | 4.65 (2.94–7.28) | 8.08 (7.59–8.60) |
| Census Region | ||
| Northeast | 3.21 (2.53–4.06) | 8.67 (8.38–8.97) |
| Midwest | 3.36 (2.79–4.05) | 7.53 (7.30–7.76) |
| South | 4.33 (3.65–5.14) | 6.35 (6.15–6.56) |
| West | 3.90 (2.98–5.07) | 8.55 (8.25–8.86) |
| Metropolitan Statistical Area | ||
| Large metro | 3.34 (2.81–3.96) | 7.76 (7.58–7.95) |
| Small metro | 4.58 (3.88–5.41) | 7.65 (7.44–7.86) |
| Nonmetro | 3.95 (3.17–4.90) | 6.50 (6.23–6.78) |
Data source: The 2002–2015 National Surveys on Drug Use and Health (NSDUH). CI=Confidence Interval.
: SAMHSA requires that any description of overall sample size based on the restricted-use data files be rounded to the nearest 100 to minimize potential disclosure risk. P-values from overall between group comparisons (pregnant women vs. non-pregnant women) for each characteristic were all <0.001. After using a Bonferroni correction to account for the 7 tests, all between group comparisons continued to reach statistical significance at the 0.05 level.